Endocrine approaches in the therapy of prostate carcinoma

Area of Science:

• Oncology
• Urology
• Endocrinology

Background:

• Management of non-organ confined prostate cancer is evolving with advances in detection and hormonal therapies.
• Classical orchiectomy has irreversible quality-of-life implications.
• Previous hormonal therapies like diethylstilbestrol and GnRH agonists have significant side effects and limited survival benefits.

Purpose of the Study:

• To review the current landscape of hormonal management for advanced prostate cancer.
• To highlight the limitations of existing therapies and the need for novel treatment strategies.
• To identify promising new therapeutic targets in prostate cancer management.

Main Methods:

• Review of existing literature on prostate cancer management and hormonal therapies.
• Analysis of the efficacy and side effect profiles of various hormonal agents.
• Discussion of emerging therapeutic approaches, including androgen receptor modification.

Main Results:

• Hormonal manipulation has yielded only modest improvements in recent decades.
• Combination therapies with antiandrogens and GnRH agonists do not improve survival and increase toxicity.
• GnRH antagonists represent a newer class of agents, but survival data are pending.

Conclusions:

• Current hormonal manipulation strategies for advanced prostate cancer offer limited clinical benefit.
• There is a critical need for novel therapeutic targets to improve patient outcomes.
• Selective androgen receptor modification represents a promising future direction for prostate cancer treatment.